TSXV - Delayed Quote CAD

DIAGNOS Inc. (ADK.V)

0.2950

-0.0050

(-1.67%)

At close: April 24 at 3:59 PM EDT

DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification

BROSSARD, Quebec, April 16, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certain critical health issues, announces today that it is working on getting new Health Canada and FDA approval on 4 additional AI analysis modules for commercialisation during Q3 2024. These additions to DIAGNOS’ service will provide our customers with a flexible AI-assisted image processing and analysis soluti

GlobeNewswire 8 days ago

DGNOF
AI & Technology Hybrid Investor Conference Agenda: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the AI & Technology Hybrid Virtual Investor Conference presented by Water Tower Research held April 10th and April 11th are now available for online viewing. REGISTER NOW AT: https://bit.ly/43SOnAB The company presentations will be available 2

GlobeNewswire 12 days ago

OSSIF

SLNH

SLNHP
AI & Technology Hybrid Investor Conference Presented by Water Tower Research Agenda Announced for April 10 and 11

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the AI & Technology Hybrid Investor Conference presented by Water Tower Research to be held April 10 and 11. The two-day conference will be broadcast at virtualinvestorconferences.com. Individual investors, institutional investors, advisors, and analy

GlobeNewswire 15 days ago

SIDU

DGNOF

CXDO
DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th

MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (ADK TSX: OTCQB: DGNOF), based in Montreal, Canada, focused on Artificial Intelligence for the medical market, today announced that André Larente, CEO, will present live at the AI & Technology Hybrid Virtual Investor Conference presented by Water Tower Research and hosted by VirtualInvestorConferences.com, on April 11th, 2024. DATE: April 11thTIME: 12:00 PM ETLINK: https://bit.ly/3PigAdMAvailable for 1x1 meetings: April 11 This will be a

GlobeNewswire 15 days ago

DGNOF
DIAGNOS Announces Grant of Stock Options

BROSSARD, Quebec, April 03, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces today a grant of 250,000 stock options to one of its directors, Mr. Philippe Couillard. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price of the stock options has been established at

GlobeNewswire 21 days ago

DGNOF
DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors

BROSSARD, Quebec, April 02, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, is pleased to announce the appointment of Dr. Philippe Couillard to the Corporation’s board of directors (the “Board”). Seasoned business advisor, neurosurgeon and former university professor, Dr. Couillard served as Premier of the province of Quebe

GlobeNewswire 22 days ago

DGNOF
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement

BROSSARD, Quebec, March 22, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing of a second and final tranche of 650,000 units (each a “Unit”) issued at a price of $0.28 per Unit, for gross proceeds of $182,000, of a non-brokered private placement initially announced on February 27, 2024 (“Private Placemen

GlobeNewswire last month

DGNOF
DIAGNOS Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line

DIAGNOS ( CVE:ADK ) Third Quarter 2024 Results Key Financial Results Revenue: CA$52.1k (down 57% from 3Q 2023). Net...

Simply Wall St. last month

DGNOF
DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors

BROSSARD, Quebec, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, is pleased to announce the appointment of Mr. Michael Braeuel to the Corporation’s board of directors (the “Board”). Mr. Braeuel has a successful track record as an accomplished entrepreneur with over 30 years of hands-on business experience. Over th

GlobeNewswire last month

DGNOF
DIAGNOS Announces Closing of First Tranche of Private Placement

BROSSARD, Quebec, Feb. 27, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing of a first tranche of 1,414,286 units (each a “Unit”) issued at a price of $0.28 per Unit, for gross proceeds of $396,000.08, of a non-brokered private placement of up to 4,285,714 units, issued at a price of $0.28 per Unit, for

GlobeNewswire last month

DGNOF
Diagnos Announces Variation in One Insider Ownership of Common Shares

BROSSARD, Québec, Feb. 23, 2024 (GLOBE NEWSWIRE) -- In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK), announces that on February 20, 2024, Mr. Tristram Coffin (the “Investor”) disposed of 800,000 common shares (each a “Share”) of the Corporation. As a result, since the last Form 62-103F1 was filed, the percentage of the Shares of the Issuer controlled by the Investor decreased by 1.98% on an undiluted basis, and by 2.62% o

GlobeNewswire last month

DGNOF
DIAGNOS recognized as a Top TSX Venture Exchange Company

BROSSARD, Quebec, Feb. 21, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its FLAIRE platform based on Artificial Intelligence (AI), is proud to announce that it has been recognized by the TSX Venture Exchange (the “TSXV” or “the Exchange”) as a 2024 Top 50 Company. The TSX Venture 50 is an annual ranking of the top-performing companies from the past year on the TSX Venture E

GlobeNewswire 2 months ago

DGNOF
DIAGNOS Appoints New Chief Operating Officer

BROSSARD, Quebec, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, is pleased to announce the appointment of Mr. Yves-Stéphane Couture as Chief Operating Officer. As part of his duties, Mr. Couture will be responsible for the continuous development of our flagship product CARA as well as its commercialization worldw

GlobeNewswire 3 months ago

DGNOF
DIAGNOS Secures Exclusive Distribution Agreement for Canada with EssilorLuxottica, a Global Leader in Vision Care

BROSSARD, Quebec, Dec. 11, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its FLAIRE platform based on Artificial Intelligence (AI), is thrilled to announce a groundbreaking strategic partnership with EssilorLuxottica, a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. This exclusive distribution agreement for Canada, sign

GlobeNewswire 4 months ago

DGNOF
DIAGNOS Announces Closing of Private Placement

BROSSARD, Québec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces the closing of a non-brokered private placement (“Private Placement”) of 1,828,717 units (each a “Unit”), issued at a price of $0.35 per Unit, for gross proceeds of $640,050.95. Each Unit consists of: - O

GlobeNewswire 4 months ago

DGNOF
DIAGNOS AI Retina Analysis is being deployed across Canada’s Largest Specialist Care Provider in Diabetes & Endocrinology

BROSSARD, Quebec, Oct. 05, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is thrilled to announce the commencement of its innovative deployment in an advanced screening program at Canada’s foremost specialist care provider in diabetes and endocrinology. The screening program is being led

GlobeNewswire 6 months ago

DGNOF
DIAGNOS Announces Closing of Private Placement and Exercise of Stock Warrants

BROSSARD, Quebec, May 18, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces the closing, today, of a non-brokered private placement (“Private Placement”) of unsecured convertible debentures (each a “Debenture”) and stock warrants (each a “Warrant”) for gross proceeds of $865,000.

GlobeNewswire 11 months ago

DGNOF
DIAGNOS and IRIS, The Visual Group strengthen partnership with the launch of “IRIS-ai powered by DIAGNOS”

IRIS-ai powered by DIAGNOS IRIS-ai powered by DIAGNOS BROSSARD, Quebec, May 17, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the launch of “IRIS-ai powered by DIAGNOS” by IRIS, The Visual Group, in partnership with DIAGNOS. For over two years, IRIS and DIAGNOS have joined forces

GlobeNewswire 11 months ago

DGNOF

Performance Overview

Return	ADK.V	S&P/TSX Composite index
YTD	-28.05%	+4.37%
1-Year	+5.36%	+5.70%
3-Year	-41.00%	+14.51%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

DIAGNOS Inc. (ADK.V)

DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification

AI & Technology Hybrid Investor Conference Agenda: Presentations Now Available for Online Viewing

AI & Technology Hybrid Investor Conference Presented by Water Tower Research Agenda Announced for April 10 and 11

DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th

DIAGNOS Announces Grant of Stock Options

DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors

DIAGNOS Announces Closing of Second and Final Tranche of Private Placement

DIAGNOS Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line

DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors

DIAGNOS Announces Closing of First Tranche of Private Placement

Diagnos Announces Variation in One Insider Ownership of Common Shares

DIAGNOS recognized as a Top TSX Venture Exchange Company

DIAGNOS Appoints New Chief Operating Officer

DIAGNOS Secures Exclusive Distribution Agreement for Canada with EssilorLuxottica, a Global Leader in Vision Care

DIAGNOS Announces Closing of Private Placement

DIAGNOS AI Retina Analysis is being deployed across Canada’s Largest Specialist Care Provider in Diabetes & Endocrinology

DIAGNOS Announces Closing of Private Placement and Exercise of Stock Warrants

DIAGNOS and IRIS, The Visual Group strengthen partnership with the launch of “IRIS-ai powered by DIAGNOS”

Performance Overview